Hemoteq AG

🎉 Celebrating 25 years Hemoteq AG and 175 years Freudenberg Group! 🎉 We celebrated the double anniversary with our employees and their close families at our new site, where construction has begun in order to triple our footprint to 130.000 sq. ft. and add 150 new jobs by 2026. 🔴 Founded in 1999 as as spin-off from RWTH Aachen University, Hemoteq AG has been a leader in the drug coatings segment for 25 years. Hemoteq's long standing legacy in the Drug Eluting Stent and Drug Coated Balloon markets is shaped by innovations, customer orientation, pioneering spirit and sustainability. In 2015, Hemoteq became part of Freudenberg Medical through a majority acquisition. This strategic integration has driven our growth and innovation with our global customer base. 🔵 The Freudenberg Group has developed throughout its 175-year history into a global technology group with 52.000 employees in about 60 countries and sales of almost €12 billion. Ground-breaking innovations, international orientation, high quality, reliability, partnership with customers and sound finances have been the company cornerstones since 1849. The highlights of the celebration included: 🎤 Speeches by Dr. Michael Hoffmann, Dr. Mark Ostwald, Dr. Max Kley and Alfred Sonders (city mayor of Alsdorf) 🎞 History videos 🎵 Live music 🎨 Children games and activities 🍗🥗🥂 Tasty food and drinks 🎊 Much fun together Thank you to all employees for your commitment and dedication. To many more years of growth and innovation together! #Hemoteq #25YearsAnniversary #Freudenberg #175YearsAnniversary #InnovatingTogether

Today it has been a pleasure to welcome Dr. Frank Heislitz, CTO, and Thomas Herr, CFO, both Members of the Board of Management at Freudenberg Group. Together with the Management Team of Hemoteq, we have discussed our business and customers, as well as our goals and exciting company development for the coming years. We've also enjoyed the tour of our new facility and are happy to see your commitment to Hemoteq AG and Freudenberg Medical. Thank you for your visit! #InnovatingTogether #Hemoteq #FreudenbergMedical

Happy Holiday

The "leave nothing behind" principle offers significant benefits and reduces risks for patients,” explains Júlia Lleixà Calvet, Director of Business Development at Freudenberg Medical & Hemoteq AG. In a recent DeviceTalks podcast interview with Kayleen Brown, she discusses the rapid adoption of drug-coated balloons and provides insights into the Paclitaxel vs. Limus debate. Hear Júlia's perspective on the latest advancements in drug/device combination products in this insightful video segment. #Innovatingtogether #Medtech #DrugCoatedBalloons

🏗️$50 M+ investment 📈 3x existing footprint 👥50% increase in staff “Huge things are happening for Freudenberg Medical and Hemoteq AG right now” highlights Kayleen Brown in a recent DeviceTalks podcast interview. Júlia Lleixà Calvet Ph.D, Director of Business Development at Freudenberg Medical & Hemoteq AG dives into some recent announcements in this video excerpt. #InnovatingTogether #Medtech #DrugCoatedBalloons

The #1 email or call… 🚀25 years of innovation ✨100+ granted patents 💪300+ team members "When engineers need expert advice on applying a drug or functional coating to a Minimally Invasive device, we’re their #1 email or call," says Júlia Lleixà Calvet, Director of Business Development at Freudenberg Medical & Hemoteq AG. Discover why in this video snippet from a recent DeviceTalks podcast. #innovatingtogether #Medtech #drugcoatedballoons

Die #Hemoteq AG wächst weiterhin und beginnt, seine Kapazitäten in Alsdorf aufzubauen. In dieser Woche durften wir unseren 300. Mitarbeitenden begrüßen, der gleichzeitig der erste offizielle Mitarbeiter in Alsdorf ist. "Herzlich willkommen, Norman😊 Wir wünschen Dir einen guten Start und viel Erfolg in der Abteilung Product Development am unserem neuen Standort in Alsdorf" ------------------------------------------------------------------------- #Hemoteq AG continues to grow and is starting to build up its capacities in Alsdorf. This week we welcomed our 300th employee, who is also the first official employee in Alsdorf. "A warm welcome, Norman😊  We wish you a good start and every success in the Product Development department at our new site in Alsdorf"

🎤 Game Changer: Drug-Coated Balloons in Focus. 🎤 Freudenberg Medical is delighted to sponsor DeviceTalks latest podcast with Janar Sathananthan, M.D., Chief Medical Officer, Interventional Cardiology Therapies at Boston Scientific, discussing the evolutionary impact of drug-eluting balloons.    In this podcast, Freudenberg Medical & Hemoteq AG’s Director Business Development Júlia Lleixà Calvet Ph.D., shares insights on the advancement of drug/device combination products from the perspective of a contract development and manufacturing partner with over 100 granted patents in the field.    Júlia also discusses the recently announced $50 million investment by Freudenberg Medical to expand capacity & capability within its drug/device business. This investment will add a second 130,000 sq. ft. facility in Aachen, Germany, tripling existing footprint and doubling workforce.    Freudenberg Medical proudly supports the DeviceTalks series with MassDevice, Tom Salemi & Kayleen Brown and is excited to contribute to the innovation conversation! Tune into the podcast below. #InnovatingTogether #Medtech #DrugCoatedBalloons

Breaking Ground on the Future of Drug/Device Combinations! Today, we celebrated the groundbreaking of our new Hemoteq AG production facility in the Aachen region, Germany, marking the next significant milestone in Freudenberg Medical's global growth journey. Key Highlights: -> Investment of more than 50 million USD to meet growing global demand for drug and hydrophilic coatings for medical devices and components -> 130,000 sq. ft. facility featuring ISO Class 7 cleanrooms, laboratories, and offices to triple our manufacturing footprint in Aachen -> Creation of more than 150 new jobs, offering exciting opportunities for talent -> Conversion of an existing industrial building to the highest environmental standards, including a PV solar power plant and state-of-the-art energy recovery systems “The convergence of medical devices and drugs is inspiring a new generation of innovative products that fundamentally improve patients’ outcomes,” said Dr. Mark Ostwald, CEO of Freudenberg Medical at today’s groundbreaking ceremony. “With this innovation driven investment, we are strengthening our position as a strategic partner to our customers, offering vertically integrated solutions along the entire supply chain.” Michael Hoffmann, CEO and founder of Hemoteq, a RWTH Aachen University spin-off, added, “Hemoteq and Freudenberg joining forces is a great success story. With this new facility, we are not only expanding our capabilities but also reaffirming our roots in the region.” Join us in celebrating this exciting development as we continue to drive innovation in medical technology. Recruitment for the new positions in operations and R&D has already begun, and we look forward to welcoming talented individuals to our team. #groundbreaking #newfacility #medtech #InnovatingTogether

Die Hemoteq AG war beim Girls‘ Day am 25. April 2024 dabei! Wir hatten 9 Mädchen, die hoch interessiert waren unsere Ballonkatheter kennenzulernen. Sie waren sehr froh in den Reinraum, ins Labor sowie in unsere Werkstatt zu gehen, um Einblick in unseren Alltag zu gewinnen. Wir bedanken uns bei den Hemoteq Kolleginnen im Organisationsteam und freuen uns sehr, dass wir unsere Schülerinnen begeistern konnten! #Hemoteq #FreudenbergMedical #GirlsDay #InnovatingTogether